Top

Published in:

01-07-2023 | Polyneuropathy | Clinical study

IV immunoglobulin well tolerated in chronic inflammatory demyelinating polyneuropathy

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Infusions of human intravenous immunoglobulin (IVIg) at doses up to 2.0 g/kg with high infusion rates are safe and well tolerated in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). …

The ProCID study was funded by Octapharma Pharmazeutika Produktionsges.m.b.H., Austria.

Cornblath DR, et al. Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study. Drug Safety : 28 Jun 2023. Available from: URL: http://doi.org/10.1007/s40264-023-01326-z

Title: IV immunoglobulin well tolerated in chronic inflammatory demyelinating polyneuropathy
Publication date: 01-07-2023
Publisher: Springer International Publishing
Keywords: Polyneuropathy
Headache
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-42978-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

IV immunoglobulin well tolerated in chronic inflammatory demyelinating polyneuropathy

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Immune-globulin/pembrolizumab/prednisone

Rifampicin/isoniazid/pyrazinamide/ethambutol

Diazoxide-related necrotising enterocolitis in neonates and infants

Levetiracetam

Tenofovir disoproxil fumarate

Multiple drugs